glp 1 shortage fda The GLP-1 drug is over. What's next for the compounders? - Pharma Technology Focus | Issue 154 What Changed? The FDA's Clarification

To harness the promising effects of GLP-1 for the development of a clinically useful drug, the short duration of action needed to be overcome

When prescribing is supervised and thoughtful, these medicines are effective and safe. Louwagie agrees that the case report highlights the need for individualized care

Zepbound starts at $299 at 2.5 mg, climbs to $399 at 5 mg, and hits $449 at 7.5 to 15 mg

M., Wang L

Let them know that they could be paying less for them by mid to late-2026

According to the FDA prescribing information, nausea occurs in approximately 15-30% of patients, vomiting in 6-12%, and diarrhea in 13-24% (rates vary by dose and indication)